Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Medical technology momentum setup: Q2 revenue grew 48% YoY to $64.1M, gross margin improved to 83%, and full-year 2026 revenue guidance was raised to $246M-$250M; the stock surged about 70% over 21 trading days and remains near recent highs.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Narrower Losses ⢠Strong Liquidity ⢠Negative Cash Flow HTFL's improving margins and narrowed loss are encouraging, but persistent cash burn, weak returns, declining equity, and high valuation multiples warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Uptrend intact ⢠Recent breakout ⢠Support watch Support Level: $48.30â$48.90 Resistance Level: $50.75 HTFL's last-month uptrend and break above $50.00 are constructive, but holding above $50.75 is key while a drop below $48.30 risks a pullback toward $45.49.
Sentiment & News
Key News Insights: ⢠Institutional accumulation ⢠Clinical validation ⢠Insider selling Institutional buying and strong FUSION trial results support Heartflow's outlook, though insider selling and competitive concerns warrant caution.
AI Summary
HTFL's shift to a coronary-intelligence platform led by Plaque Analysis offers meaningful upside, but its premium valuation already prices in successful reimbursement, adoption, and scaling; investors should wait for sustained declining free-cash-flow burn and proof of durable commercialization before adding exposure.
Description
HeartFlow offers a non-invasive diagnostic platform that converts a single coronary CT angiogram into a patient-specific 3D heart model and applies computational fluid dynamics and related analytics to quantify blood flow, arterial narrowing, and plaque characteristics. Founded in 2007 and based in Mountain View, California, the company distributes its technology globally to support clinical assessment and management of coronary artery disease.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 17 | Aug 24 | HTFL | Heartflow, Inc. Common Stock | Medical technology momentum setup: Q2 revenue grew 48% YoY to $64.1M, gross margin improved to 83%, and full-year 2026 revenue guidance was raised to $246M-$250M; the stock surged about 70% over 21 trading days and remains near recent highs. | Closed | +19.7% |
| Mar 23 | Mar 30 | HTFL | Heartflow, Inc. Common Stock | HeartFlow (HTFL) has multiple fresh growth catalystsâAetna coverage expansion Jan 6, 2026, new clinical data at ACC and the launch/enrollment of the 5,000âpatient NAVIGATEâPCI registry on March 16, 2026âand its stock has surged ~20â30% off the March low, positioning it as a highâbeta, event-driven healthcare IT momentum trade despite ongoing operating losses. | Closed | -11.0% |